PROTEINS IMPORTANT FOR PROGRAMMED CELL DEATH AND FOR GENE-LINKED BLINDNESS
PROTEINS IMPORTANT FOR PROGRAMMED CELL DEATH AND FOR GENE-LINKED BLINDNESS
批准号:
8362355
负责人:
CHARLES EIGENBROT
金额:
$0.14万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-03-01 至 2012-02-29
关键词:
Age related macular degenerationAmino AcidsApoptosisApoptosis InhibitorApoptoticBindingBlindnessC-terminalCell DeathDNA Sequence RearrangementDataDistantEventFundingGenesGrantHomologous GeneHumanImmunoglobulin FragmentsInhibition of ApoptosisInsulin-Like Growth-Factor-Binding ProteinsLearningLinkLocationN-terminalNational Center for Research ResourcesPeptide HydrolasesPopulationPredispositionPrincipal InvestigatorProtease DomainProtein Binding DomainProteinsRadiationResearchResearch InfrastructureResourcesRoleSourceUbiquitinationUnited States National Institutes of HealthVariantblocking factorcancer therapycostdimermolecular shapemonomeroverexpressionsmall moleculestructural biologyubiquitin-protein ligase
中文摘要
这个子项目是利用资源的许多研究子项目之一。
由NIH/NCRR资助的中心拨款提供。对子项目的主要支持
子项目的首席调查员可能是由其他来源提供的,
包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能
表示该子项目使用的中心基础设施的估计数量,
不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。
细胞凋亡抑制因子(IAPs)是一种能阻断细胞死亡的抗凋亡因子。IAP含有蛋白质-蛋白质相互作用结构域和一个赋予E3泛素连接酶活性的C-末端环区。小分子拮抗剂与细胞IAP的结合促进了CIAP的自身泛素化和随后的蛋白酶体降解,从而释放了CIAP对细胞凋亡的抑制--这种情况可能会使一些癌症治疗更有效。远距离拮抗剂结合事件如何影响物理上不同的环区的E3连接酶活性尚不清楚。我们的初步数据支持这样一种假设,即拮抗剂结合导致结构重排,从而允许形成活性的环-环二聚体。此外,拮抗剂还可以促进中等大小的cIAP1群体;比单体大,但比二聚体小。这种形式的cIAP1在特定单价拮抗剂存在的情况下是优势物种,可能代表蛋白质的开放形式,但不是二聚体。我们从没有和存在小分子拮抗剂的情况下从cIAP1获得SAXS数据。HTRA1是一种多结构域的蛋白酶。人类HTRA1基因的变异促进了过度表达,增加了老年性黄斑变性的易感性。HTRA1由四个结构域组成,其分子形状已知,其蛋白酶活性需要形成一个1440个氨基酸的非共价同源三聚体。非蛋白酶域的功能作用尚不清楚。由IGFBP-RP结构域和Kazal结构域组成的N-末端结构域在两种同系物中缺失,表明其具有独特的调控功能。我们的目标是了解三聚体中的结构域位置、潜在的结构域相互作用和结构域齐聚状态。此外,我们还发现了可能有助于SAXS分析的抗HTRA1抗体片段。
英文摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
Inhibitors of apoptosis (IAPs) are anti-apoptotic factors that block cell death. IAPs contain protein-protein interaction domains and a C-terminal RING domain that confers E3 ubiquitin ligase activity. Binding of small molecule antagonists to cellular IAPs promotes cIAP auto-ubiquitination and subsequent proteasomal degradation, thereby releasing cIAP inhibition of apoptosis?a situation that may render some cancer therapies more effective. How the distant antagonist binding event influences the E3 ligase activity of the physically distinct RING domain is unclear. Our preliminary data support a hypothesis where antagonist binding leads to a structural rearrangement that permits formation of active RING-RING dimers. Moreover, antagonists can also promote a cIAP1 population of intermediate size; larger than monomer, yet smaller than a dimer. This form of cIAP1 is the dominant species in the presence of a particular monovalent antagonist and may represent the ?open?, but un-dimerized, form of the protein. We seek SAXS data from cIAP1 both in the absence and presence of small molecule antagonists. Htra1 is a multi-domain protease. A variant human Htra1 gene promotes overexpression and increases susceptibility to age-related macular degeneration. Htra1 is composed of four domains for which molecular shapes are known by homology and its protease activity requires formation of a non-covalent homotrimer of 1440 amino acids. The functional roles of the non-protease domains are not clear. The N-terminal domain composed of the IGFBP-rP and Kazal domains is absent in baterial homologues, suggesting a unique regulatory function. Our objective is to learn the domain locations in the trimer, potential domain interactions and domain oligomerization status. In addition, we have anti-Htra1 antibody fragments which may aid in SAXS analysis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CIAP CONFORMATIONAL CHANGE AND OLIGOMERIZATION CAUSED BY A SMALL MOLECULE ANTAGO
-
批准号:8362260
-
项目类别:
-
资助金额:$0.03万
-
财政年份:2011
-
负责人:CHARLES EIGENBROT
-
依托单位:
INHIBITOR OF APOPTOSIS PROTEINS: DOMAIN ORGANIZATION AND CONFORMATIONAL REARRANG
-
批准号:8362368
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2011
-
负责人:CHARLES EIGENBROT
-
依托单位:
GENENTECH PARTNER TIME
-
批准号:8362135
-
项目类别:
-
资助金额:$0.74万
-
财政年份:2011
-
负责人:CHARLES EIGENBROT
-
依托单位:
GENENTECH PARTNER TIME
-
批准号:8170064
-
项目类别:
-
资助金额:$0.71万
-
财政年份:2010
-
负责人:CHARLES EIGENBROT
-
依托单位:
PROTEINS IMPORTANT FOR PROGRAMMED CELL DEATH AND FOR GENE-LINKED BLINDNESS
-
批准号:8170360
-
项目类别:
-
资助金额:$0.03万
-
财政年份:2010
-
负责人:CHARLES EIGENBROT
-
依托单位:
CIAP CONFORMATIONAL CHANGE AND OLIGOMERIZATION CAUSED BY A SMALL MOLECULE ANTAGO
-
批准号:8170244
-
项目类别:
-
资助金额:$0.1万
-
财政年份:2010
-
负责人:CHARLES EIGENBROT
-
依托单位:
OLIGOMERIC STATE OF ERBB-FAMILY EXTRACELLULAR DOMAIN +/- ANTIBODY FRAGMENT
-
批准号:8170230
-
项目类别:
-
资助金额:$0.1万
-
财政年份:2010
-
负责人:CHARLES EIGENBROT
-
依托单位:
GENENTECH PARTNER TIME
-
批准号:7954389
-
项目类别:
-
资助金额:$0.37万
-
财政年份:2009
-
负责人:CHARLES EIGENBROT
-
依托单位:
GENENTECH PARTNER TIME
-
批准号:7722050
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2008
-
负责人:CHARLES EIGENBROT
-
依托单位:
STRUCTURAL STUDIES OF TNFL-TNFR COMPLEXES INCLUDING BLYS-BR3
-
批准号:7597918
-
项目类别:
-
资助金额:$0.38万
-
财政年份:2007
-
负责人:CHARLES EIGENBROT
-
依托单位:
GENENTECH PARTNER TIME
-
批准号:7598311
-
项目类别:
-
资助金额:$0.02万
-
财政年份:2007
-
负责人:CHARLES EIGENBROT
-
依托单位:
STRUCTURAL STUDIES OF TNFL-TNFR COMPLEXES INCLUDING BLYS-BR3
-
批准号:7370373
-
项目类别:
-
资助金额:$0.26万
-
财政年份:2006
-
负责人:CHARLES EIGENBROT
-
依托单位:
STRUCTURAL STUDIES OF TNFL-TNFR COMPLEXES INCLUDING BLYS-BR3
-
批准号:7180373
-
项目类别:
-
资助金额:$0.1万
-
财政年份:2005
-
负责人:CHARLES EIGENBROT
-
依托单位:
STRUCTURAL STUDIES OF TNF AND TNFR FAMILY MEMBERS
-
批准号:6977197
-
项目类别:
-
资助金额:$0.32万
-
财政年份:2004
-
负责人:CHARLES EIGENBROT
-
依托单位:
STRUCTURE OF TNFL-TNFR COMPLEXES INCLUDING BLYS-BR3
-
批准号:6976263
-
项目类别:
-
资助金额:$0.11万
-
财政年份:2004
-
负责人:CHARLES EIGENBROT
-
依托单位:
海外基金